Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

“The Novartis collaboration presents an extraordinary opportunity to leverage our unbiased genetic screening platform and proprietary chemical libraries to address novel, high-value targets previously ...

Forbes explains how the strategy would work. Meanwhile, Aetna has accused several drugmakers of conspiring to overcharge the company, consumers, and the federal government for generic drugs.

Aetna is taking legal action against Pfizer, Novartis, Teva Pharmaceuticals and others, saying the list of drugmakers ...

Novartis reports positive Phase III trial results for its gene therapy in spinal muscular atrophy Type 2, plans regulatory ...

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed. The case furthe ...

The Canada Border Services Agency says a man from Sicamous, B.C., is facing firearms and drug trafficking charges after officers intercepted a package addressed to him earlier this year.

Novartis agreed in 2020 to pay more than $729 million to settle U.S. government charges it paid illegal kickbacks to doctors and patients to boost drug sales. The case is US ex rel Camburn v.

NEW YORK (Reuters) -A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster ...